Edinburgh-based company Concinnity Genetics has successfully raised £3 million in seed funding to further develop its innovative gene control systems for safer gene therapies. The investment round was oversubscribed and was led by Eos Advisory, with support from Scottish Enterprise, Old College Capital, and Maven Capital Partners. The company plans to spin out from the lab of Professor Susan Rosser and establish operations in Scotland’s thriving life science hub.
Company Information
Company
Concinnity Genetics
Location
Edinburgh, Scotland, United Kingdom
About
Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.
EdinburghBiotechnologyHealth CareArtificial Intelligence